- Previous Close
3.4600 - Open
3.4100 - Bid 2.4700 x 200
- Ask 4.1800 x 200
- Day's Range
3.2200 - 3.4100 - 52 Week Range
3.0400 - 8.4400 - Volume
137,170 - Avg. Volume
199,703 - Market Cap (intraday)
178.493M - Beta (5Y Monthly) 1.17
- PE Ratio (TTM)
37.33 - EPS (TTM)
0.0900 - Earnings Date May 5, 2025 - May 9, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.47
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and meet other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.
www.biote.com217
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: BTMD
View MorePerformance Overview: BTMD
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BTMD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BTMD
View MoreValuation Measures
Market Cap
108.94M
Enterprise Value
180.46M
Trailing P/E
38.44
Forward P/E
6.53
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.60
Price/Book (mrq)
--
Enterprise Value/Revenue
0.92
Enterprise Value/EBITDA
11.57
Financial Highlights
Profitability and Income Statement
Profit Margin
1.60%
Return on Assets (ttm)
16.96%
Return on Equity (ttm)
--
Revenue (ttm)
197.19M
Net Income Avi to Common (ttm)
3.16M
Diluted EPS (ttm)
0.0900
Balance Sheet and Cash Flow
Total Cash (mrq)
39.34M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
56.49M